特布他林对哮喘急性期疗效及细胞因子的影响观察  

Observing the Influence of Terbutaline to the Acute Asthma and Cytokines

作　　者：潘林艳[1] 郑纪阳[1] 池琼[1] 戴新建[1] 王万铁[2] 

机构地区：[1]温州市中心医院呼吸内科 [2]温州医科大学病理生理学教研室,温州325035

出　　处：《数理医药学杂志》2016年第6期802-804,共3页Journal of Mathematical Medicine

摘　　要：目的：观察布特布他林对哮喘急性期及免疫指标的影响.方法：将某科室2014年32月～2015年3月收治的急性期哮喘患者75例按随机、双盲原则分为观察组38例和对照组37例,所有纳入病例均符合《支气管哮喘防治指南》.对照组给予布地奈德单独用药,观察组给予特布他林联合布地奈德治疗,观察两组患者白细胞介素-6（IL-6）、白细胞介素-1（IL-1）、超敏-C 反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNκ-α）等炎症因子变化及临床疗效情况.结果：两组治疗后白细胞介素-6、白细胞介素-1、超敏-C 反应蛋白、肿瘤坏死因子-α均有所下降,但是观察组下降更为显著,两组相比,差异有显著性（P〈0.05）;观察组患者治疗后的总有效率为89.47%,明显高于对照组72.97%,差异有显著性（P〈0.05）.结论：特布他林可有效降低血清炎症因子的水平,改善哮喘患者症状,值得临床推广和应用.Objective:To observe the effect of terbutaline for asthma acute and immunity index.Methods:75cases of acute asthma from March 2014~March 2015,were treated randomized,double-blind principle divided into observation group of 38 cases and a control group of 37 cases,all cases were included in line 'Bronchial Asthma Guide'.The control group received budesonidealone medication,observation group were given budesonide with terbutaline therapy,were observed interleukin-6(IL-6),interleukin-1(IL-1),Ultra Min-C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)and other inflammatory factors and changes in clinical efficacy.Results:After treatment,interleukin-6,interleukin-1,hypersensitivity-C-reactive protein,tumor necrosis factor-αhas declined,but the observation group decreased more significantly,compared the two groups,the difference significant(P<0.05);the total effective rate was observed in patients after treatment 89.47%,significantly higher than 72.97%,the difference was significant(P<0.05).Conclusion:Terbutaline can effectively reduce serum levels of inflammatory cytokines,improve symptoms in patients with asthma,and is worthy of clinical application.

关 键 词：特布他林 哮喘急性期 免疫指标 

分 类 号：R725.6[医药卫生—儿科]